Xellia Pharmaceuticals, based in Denmark, specialises in the supply of anti-infective drugs and will supply Civica Rx with antibiotics, including vancomycin and daptomycin – treatments for a variety of infections, as well as those that are potentially life-threatening.
The agreement is the first time that Civica Rx has secured a contract for the supply of generic drugs.
Martin Van Trieste, CEO of Civica, “By helping to stabilise the supply of vancomycin and daptomycin, we will have a direct impact on patient safety and public health by providing consistent access to antibiotics that are important treatment options in the management of difficult-to-treat and life-threatening infections.”
Civica was set up to improve the supply of generic medicines across its network, which has reached 800 hospitals in number.
The non-profit is approaching its aim of improving generic access with a three-pronged approach: in deals such as this, by setting up a supply agreement, by developing or acquiring new drug applications (NDAs), and buying or building manufacturing facilities.
A spokesperson for the company previously told us that the organisation was set up to combat the disruption that occurs when a “long and fragile supply chain” is served by only one or two manufacturers.
Civica is planning on delivering 14 generics medicines to its network of hospitals by the end of 2019.
For Xellia, the company stated that it is expanding its manufacturing and sales capabilities within the US, with the agreement with Civica being part of this strategy.
The products produced by the collaboration will see Xellia manufacturing the medication for Civica under its abbreviated NDA, under the latter’s labelling and new drug code.
